Travere Therapeutics (TVTX) Receivables (2014 - 2026)
Travere Therapeutics posted quarterly Receivables of $88.5 million for Q1 2026, up 142.6% year-on-year from $36.5 million in Q1 2025, and up 8.72% on a QoQ basis from $81.4 million in Q4 2025.
Travere Therapeutics (TVTX) has 13 years of Receivables data on file, last reported at $88.5 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables rose 142.6% year-over-year to $88.5 million; the trailing twelve-month figure through Mar 2026 stood at $88.5 million (up 142.6% YoY), and the FY2025 full-year result was $81.4 million, up 176.72% from the prior year.
- Receivables for Q1 2026 stood at $88.5 million, up from $81.4 million in the prior quarter.
- Across five years, Receivables topped out at $88.5 million in Q1 2026 and bottomed at $12.7 million in Q3 2022.
- The 5-year median for Receivables is $26.5 million (2024), against an average of $35.0 million.
- The widest annual swing landed in 2022, when Receivables declined 5.45%; it then soared 205.33% in 2025.
- A 5-year view of Receivables shows it stood at $18.5 million in 2022, then jumped by 39.0% to $25.8 million in 2023, then advanced by 14.11% to $29.4 million in 2024, then soared by 176.72% to $81.4 million in 2025, then grew by 8.72% to $88.5 million in 2026.
- The last three Receivables figures came in at $88.5 million (Q1 2026), $81.4 million (Q4 2025), and $84.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Travere Therapeutics | 4.14 Bn | 4.06 Bn | 102.38 Mn | 88.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.50 Mn |
| Dec 31, 2025 | 81.40 Mn |
| Sep 30, 2025 | 84.48 Mn |
| Jun 30, 2025 | 40.22 Mn |
| Mar 31, 2025 | 36.48 Mn |
| Dec 31, 2024 | 29.42 Mn |
| Sep 30, 2024 | 27.67 Mn |
| Jun 30, 2024 | 27.27 Mn |
| Mar 31, 2024 | 26.50 Mn |
| Dec 31, 2023 | 25.78 Mn |
| Sep 30, 2023 | 18.70 Mn |
| Jun 30, 2023 | 22.90 Mn |
| Mar 31, 2023 | 23.54 Mn |
| Dec 31, 2022 | 18.55 Mn |
| Sep 30, 2022 | 12.67 Mn |
| Jun 30, 2022 | 16.69 Mn |
| Mar 31, 2022 | 14.68 Mn |
| Dec 31, 2021 | 16.81 Mn |
| Sep 30, 2021 | 13.40 Mn |
| Jun 30, 2021 | 11.90 Mn |
| Mar 31, 2021 | 13.07 Mn |
| Dec 31, 2020 | 15.93 Mn |
| Sep 30, 2020 | 15.03 Mn |
| Jun 30, 2020 | 14.10 Mn |
| Mar 31, 2020 | 18.10 Mn |
| Dec 31, 2019 | 18.05 Mn |
| Sep 30, 2019 | 16.80 Mn |
| Jun 30, 2019 | 15.45 Mn |
| Mar 31, 2019 | 12.71 Mn |
| Dec 31, 2018 | 12.66 Mn |
| Sep 30, 2018 | 13.50 Mn |
| Jun 30, 2018 | 12.89 Mn |
| Mar 31, 2018 | 12.98 Mn |
| Dec 31, 2017 | 13.87 Mn |
| Sep 30, 2017 | 14.54 Mn |
| Jun 30, 2017 | 13.32 Mn |
| Mar 31, 2017 | 15.43 Mn |
| Dec 31, 2016 | 18.51 Mn |
| Sep 30, 2016 | 14.96 Mn |
| Jun 30, 2016 | 16.57 Mn |
| Mar 31, 2016 | 13.40 Mn |
| Dec 31, 2015 | 12.46 Mn |
| Sep 30, 2015 | 13.50 Mn |
| Jun 30, 2015 | 11.47 Mn |
| Mar 31, 2015 | 8.16 Mn |
| Dec 31, 2014 | 7.96 Mn |
| Sep 30, 2014 | 4.68 Mn |
| Jun 30, 2014 | 7.56 Mn |
| Mar 31, 2014 | 28,800.00 |